-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Neuromyelitis Optica (Devic’s Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Neuromyelitis Optica (Devic's Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Neuromyelitis Optica (Devic's Syndrome) Drug Details: Rituximab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PIPE-791 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PIPE-791 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PIPE-791 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RNS-60 in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RNS-60 in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RNS-60 in Acute Ischemic Stroke Drug Details: RNS-60 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-97540 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-97540 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-97540 in Secondary Progressive Multiple Sclerosis (SPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-97540 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-97540 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-97540 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-97540 in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-97540 in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-97540 in Relapsing Multiple Sclerosis (RMS) Drug Details: CC-97540...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6035 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6035 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Marginal Zone B-cell Lymphoma Drug Details: Rituximab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Hairy Cell Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Hairy Cell Leukemia Drug Details: Rituximab (MabThera, Rituxan,...